Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 195940.KQ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 195940.KQ and 80,000+ other tickers.
See exactly how 195940.KQ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 195940.KQ and 80,000+ other tickers.
Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N Corporation operates as a pharmaceutical enterprise. The company boasts a comprehensive portfolio of prescription medications designed to address a wide array of medical conditions. These include treatments for various infectious diseases, such as those caused by gram-positive and gram-negative bacteria, vancomycin-resistant Enterococcus faecium, acute bacterial sinusitis, bronchitis, and pneumonia. Their therapeutic offerings also extend to chronic illnesses like anemia, diabetes, hypertension (including cases with…
No recent news available.